A tighter archive for life-science signals.
Search once, then narrow by source or topic.
What macro factors could drive Waters Corporation (WAZ) stock higher - Portfolio Update Report & Expert Approved Momentum Trade Ideas - newser.com
What macro factors could drive Waters Corporation (WAZ) stock higher - Portfolio Update Report & Expert Approved Momentum Trade Ideas newser.com
Why Agilent Technologies Inc. stock stays resilient - Stop Loss & Daily Stock Momentum Reports - newser.com
Why Agilent Technologies Inc. stock stays resilient - Stop Loss & Daily Stock Momentum Reports newser.com
Measuring Agilent Technologies Inc.’s beta against major indices - July 2025 Trends & Free Real-Time Market Sentiment Alerts - newser.com
Measuring Agilent Technologies Inc.’s beta against major indices - July 2025 Trends & Free Real-Time Market Sentiment Alerts newser.com
Will Waters Corporation (WAZ) stock outperform energy sector in 2025 - Portfolio Update Report & Long-Term Safe Investment Plans - newser.com
Will Waters Corporation (WAZ) stock outperform energy sector in 2025 - Portfolio Update Report & Long-Term Safe Investment Plans newser.com
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - Yahoo Finance
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in...
Is Agilent Technologies Inc. (AG8) stock prepared for digital transition - Weekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Is Agilent Technologies Inc. (AG8) stock prepared for digital transition - Weekly Investment Recap & AI Based Buy and Sell Signals newser.com
CRISPR/Cas9 Knock-In Tagging: Simplifying the Study of Endogenous Biology
Understanding the expression, function and dynamics of proteins in their native environment is a fundamental goal that’s common to diverse aspects of molecular and cell...
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S. - PR Newswire
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S. PR Newswire
New experimental drug could transform care for cancer patients - The Independent
New experimental drug could transform care for cancer patients The Independent
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? - simplywall.st
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? simplywall.st
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
Developing a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
How Lonza Group AG (Common Stock) (LO3A) stock reacts to stronger dollar - Portfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
How Lonza Group AG (Common Stock) (LO3A) stock reacts to stronger dollar - Portfolio Risk Report & Free Long-Term Investment Growth Plans newser.com
Agilent Technologies (A): Is the Stock Undervalued After Recent Momentum Cools? - simplywall.st
United States/Life Sciences/NYSE:A Agilent Technologies (A): Is the Stock Undervalued After Recent Momentum Cools? Simply Wall St Reviewed by Simply Wall St November 14...
10x Genomics Announces Chief Legal Officer Retirement - TipRanks
10x Genomics Announces Chief Legal Officer Retirement TipRanks
Piper Sandler Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
Piper Sandler Maintains 10x Genomics (TXG) Neutral Recommendation Nasdaq
Roche's experimental MS drug hits main goal in one of two key trials - Reuters
Roche's experimental MS drug hits main goal in one of two key trials Reuters
Roche Rival Plunges On 'Unprecedented' Results In MS Treatment - Investor's Business Daily
Roche Rival Plunges On 'Unprecedented' Results In MS Treatment Investor's Business Daily
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page